Medically Reviewed By

Dr. Ian Strand, DO, FAAMM

May 20, 2026 Weight Loss GLP-1

Retatrutide vs Tirzepatide: What the Data Actually Shows

Every few years, a new weight loss medication enters the conversation with claims of being more effective than what came before. Most of the time, the claims do not hold up. Retatrutide is one of the rare exceptions where the early data is genuinely striking, and the natural question is how it compares to tirzepatide, the current benchmark.

This article covers what each medication is, what the trials actually show, how they differ in mechanism and side effects, where each one stands on availability, and how the two compare clinically.

What Is Tirzepatide?

Tirzepatide is a once-weekly injectable medication developed by Eli Lilly. It works by activating two gut hormone receptors at the same time: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism reduces appetite, slows gastric emptying, improves insulin sensitivity, and lowers blood sugar.

The FDA approved tirzepatide for type 2 diabetes (brand name Mounjaro) in May 2022, and again for chronic weight management (brand name Zepbound) in November 2023.

In the SURMOUNT-1 trial, adults with obesity who took the highest tirzepatide dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks, compared with about 3.1% on placebo, using the treatment-regimen estimand. These results placed tirzepatide ahead of semaglutide (Wegovy), which produces around 15% body weight loss in similar trials, and made it the most effective approved weight loss medication on the market.

What Is Retatrutide?

Retatrutide is also being developed by Eli Lilly. The critical difference is that it activates three receptors instead of two: GLP-1, GIP, and glucagon. Tirzepatide hits the first two. Retatrutide adds the glucagon receptor, which is what makes it a "triple agonist."

The glucagon arm is what makes retatrutide distinctive. Glucagon is best known for raising blood sugar, which sounds counterproductive in a diabetes or weight loss drug. But glucagon is also associated with increased energy expenditure and lipolysis (the breakdown of stored fat). When activated alongside GLP-1 and GIP, the glucose-raising effect is offset, and the proposed net result is greater fat loss with maintained metabolic stability. It is worth noting that energy expenditure was not directly measured in the human obesity trials, so this mechanism is supported by preclinical and mechanistic evidence rather than measured directly in patients.

In the Phase 2 trial published in the New England Journal of Medicine in 2023, adults with obesity on the highest retatrutide dose (12 mg weekly) lost an average of 24.2% of their body weight at 48 weeks, with the trial authors noting that weight loss had not yet plateaued at that point.

Phase 3 data has since followed. In December 2025, Eli Lilly reported topline results from TRIUMPH-4, a registration trial in adults with obesity or overweight and knee osteoarthritis, without diabetes. On the treatment-regimen estimand — the same analysis used for the tirzepatide figures above — retatrutide 12 mg produced about 23.7% body weight loss at 68 weeks. (On the efficacy estimand, which assumes full adherence, the figure was higher, at 28.7%.) These are topline results from a specific comorbid population and have not yet been peer-reviewed. Seven additional Phase 3 trials across the TRIUMPH program, in obesity and type 2 diabetes, are expected to complete in 2026.

Retatrutide remains investigational and is not yet FDA-approved.

Retatrutide vs Tirzepatide: Side-by-Side

The two medications share a developer and a delivery format (once-weekly subcutaneous injection), but differ in mechanism, regulatory status, and what is known about long-term safety. Weight loss figures below use the treatment-regimen estimand for both drugs.

Side Effects: What Is Different?

Both medications share the same dominant side effect profile, which is unsurprising given the shared GLP-1 and GIP mechanism. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be most intense during dose escalation and improve as the body adjusts.

The notable difference is a sensory one. In TRIUMPH-4, retatrutide produced a dose-related dysesthesia signal, meaning altered or uncomfortable skin sensations such as tingling or hypersensitivity, in about 8.8% of patients at the 9 mg dose and 20.9% at the 12 mg dose, versus 0.7% on placebo. These events were generally mild and rarely led to discontinuation. Dysesthesia is not seen to any comparable degree with tirzepatide.

Tirzepatide's side effect profile is well-characterized after more than three years of post-market use across millions of patients. Retatrutide's profile is still being built as Phase 3 data matures, which is the main reason its overall benefit-risk picture is less settled than tirzepatide's at this stage.

Availability and Regulatory Status

Tirzepatide is FDA-approved and available by prescription under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Through Lilly's self-pay channel, single-dose vials run roughly $300 to $450 per month without insurance.

Retatrutide is not FDA-approved. It is an investigational drug still in Phase 3 testing, and the established route to receive it is enrollment in one of the ongoing TRIUMPH clinical trials. Based on typical timelines for a New Drug Application followed by FDA review, the earliest realistic brand-name approval is 2027 to 2028.

How the Two Compare Clinically

Tirzepatide has the longer real-world track record. After three years on the market, its safety profile, drug interactions, and long-term response patterns are well-characterized, which makes it the established option for medical weight management today.

Retatrutide distinguishes itself through its third receptor target. Glucagon receptor activation is associated with increased energy expenditure and lipolysis in mechanistic and preclinical work, and both the Phase 2 and Phase 3 efficacy data are consistent with a meaningful metabolic effect. On a matched treatment-regimen basis its weight loss numbers run modestly ahead of tirzepatide's, though in different trial populations. That potential advantage is balanced, for now, by its investigational status and a still-maturing safety profile.

Both share a once-weekly subcutaneous format and a similar dose-escalation pattern. For the time being, tirzepatide is the only one of the two that is an approved, available treatment; retatrutide's role in practice will depend on whether and when it reaches approval.

Frequently Asked Questions